Jeil Pharmaceutical Launches Diabetes Treatments Tenefil and Tenefil Plus

Cheil Pharmaceutical's diabetes treatments Tenefil and Tenefil Plus.
[Photo by Cheil Pharmaceutical]

[Asia Economy Reporter Lee Gwan-joo] Jeil Pharmaceutical announced on the 2nd that it has launched the DPP-4 inhibitor class diabetes treatments 'Tenefil' (active ingredient Teneligliptin) and 'Tenefil Plus' (active ingredients Teneligliptin and Metformin).

Tenefil is a diabetes treatment that lowers blood sugar by inhibiting the DPP-4 enzyme, which raises blood glucose levels in the body. It is used as an adjunct to diet and exercise therapy to improve blood sugar control in diabetic patients.

The main ingredient of Tenefil, Teneligliptin, is one of the DPP-4 inhibitors used to treat type 2 diabetes. It increases insulin secretion, resulting in a blood sugar-lowering effect. Notably, among DPP-4 inhibitors, it rapidly lowers glycated hemoglobin (HbA1c) levels within a short period, allows blood sugar control with once-daily dosing, and can be prescribed to patients with renal impairment without dosage adjustment.

Additionally, Jeil Pharmaceutical supplies ‘Tenefil Plus,’ a combination of Teneligliptin and Metformin. Beyond DPP-4 inhibitors, Jeil Pharmaceutical plans to introduce various classes of oral hypoglycemic agents, including SGLT-2 inhibitors and thiazolidinediones (TZD).

A Jeil Pharmaceutical representative stated, “We plan to further strengthen our position in the diabetes treatment market by leveraging our long-accumulated marketing know-how and sales network,” adding, “We will strive to provide optimal treatment options for diabetic patients and expand accessibility.”